Surpassing 100,000 patients treated is an impressive milestone. It is a testament to the significant clinical value that our technology provides patients and physicians in the electrophysiology field. It also is a reminder of the robust validation of our technology. Stereotaxis stands head-and-shoulders above all others as the global leader in endovascular robotics.
I want to thank and congratulate all the employees, physicians, hospital administrators, corporate partners and investors who made reaching this milestone possible. There is a saying that whoever saves a life is considered to have saved an entire world. We take great pride in each patient we treat and life we improve. We look forward to continuing to advance our technology and support robotic ablation practices such that hundreds of thousands of additional patients suffering from arrhythmias can benefit from the precision and safety that robotics provides.
– David Fischel
Acting Chief Executive Officer and Chairman of the Board